Kiora Pharmaceuticals (KPRX) Net Equity Issued and Repurchased (2015 - 2023)

Kiora Pharmaceuticals (KPRX) has 9 years of Net Equity Issued and Repurchased data on file, last reported at $5.9 million in Q4 2023.

• Quarterly Net Equity Issued and Repurchased rose 9.39% year-over-year to $5.9 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $5.9 million (up 4.69% YoY) and the FY2023 annual result came in at $6.3 million, up 17.61% from the prior year.
• Net Equity Issued and Repurchased rose to $5.9 million in Q4 2023, from $142310.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $9.8 million in Q3 2021 to a low of $98960.0 in Q1 2023.
• A 5-year average of $4.0 million and a median of $4.5 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2020 — Net Equity Issued and Repurchased plunged 73.4% — and 2021, when it jumped 77.48%.
• Tracing KPRX's Net Equity Issued and Repurchased over 5 years: stood at $1.9 million in 2019, then slumped by 73.4% to $498687.0 in 2020, then surged by 1856.41% to $9.8 million in 2021, then plunged by 44.88% to $5.4 million in 2022, then grew by 9.39% to $5.9 million in 2023.
• The last three Net Equity Issued and Repurchased figures came in at $5.9 million (Q4 2023), $142310.0 (Q2 2023), and $98960.0 (Q1 2023), per Business Quant data.